From: Association of serum uric acid levels with COVID-19 severity
 | Item No | Recommendation | Page No |
---|---|---|---|
Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 1 |
(b) Provide in the abstract an informative and balanced summary of what was done and what was found | 5–7 | ||
Introduction | |||
 Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 8–9 |
 Objectives | 3 | State specific objectives, including any prespecified hypotheses | 9–10 |
Methods | |||
 Study design | 4 | Present key elements of study design early in the paper | 10–12 |
 Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 10–12 |
 Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | 10–11 |
(b) For matched studies, give matching criteria and the number of controls per case | 10–11 | ||
 Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 10–12 |
 Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 10–12 |
 Bias | 9 | Describe any efforts to address potential sources of bias | 10–12 |
 Study size | 10 | Explain how the study size was arrived at | 10–11 |
 Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 11–12 |
 Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 12–13 |
(b) Describe any methods used to examine subgroups and interactions | 12–13 | ||
(c) Explain how missing data were addressed | 10 | ||
(d) If applicable, explain how matching of cases and controls was addressed | 10–11 | ||
(e) Describe any sensitivity analyses | 12–13 | ||
Results | |||
 Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 13–14 |
(b) Give reasons for non-participation at each stage | – | ||
(c) Consider use of a flow diagram | 14 | ||
 Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 13–14 |
(b) Indicate number of participants with missing data for each variable of interest | – | ||
 Outcome data | 15* | Report numbers in each exposure category, or summary measures of exposure | 14–17 |
 Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 14–17 |
(b) Report category boundaries when continuous variables were categorized | 14–17 | ||
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 14–17 | ||
 Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | – |
Discussion | |||
 Key results | 18 | Summarise key results with reference to study objectives | 18–21 |
 Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 22–23 |
 Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 21–22 |
 Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 21–22 |
Other information | |||
 Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 23 |